HVE Stock Chart & Stats
€20.40
€0.00(0.00%)
At close: 4:00 PM EST
€20.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€14.20 - €21.20
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€1.39B
Enterprise Value€1.70K
Total Cash (Recent Filing)€611.93M
Total Debt (Recent Filing)€331.42M
Price to Earnings (P/E)3.1
Beta0.17
Next Earnings
Jul 29, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.02
Shares Outstanding73,808,750
10 Day Avg. Volume0
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)3.17
P/FCF Ratio7.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.03Price Target Upside52.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)3.13
Revenue Forecast (FY)€385.93M
Bulls Say, Bears Say
Bulls Say
Strong TTM ProfitabilityVery high trailing-twelve-month margins and a sharp earnings rebound indicate durable core earnings power from Innoviva’s asset-heavy model. High margins provide structural capacity to fund investments, buybacks or shareholder returns and absorb partner sales variability over months.
Improved Balance Sheet FlexibilityMeaningful equity growth and modest current leverage enhance financial flexibility for acquisitions, asset monetizations and capital support to portfolio companies. A stronger balance sheet lowers refinancing risk and supports multi-quarter strategic deployment of cash.
Consistent Positive Cash GenerationConsistently positive operating and free cash flow across reported periods shows the company converts earnings to cash reliably. This persistent cash generation supports recurring distributions, opportunistic investments and reduces dependence on external financing over the medium term.
Bears Say
Earnings And Cash VolatilityWide year-to-year swings in profitability and choppy free cash flow growth undermine predictability of core cash returns. Volatility complicates forecasting for asset monetization and capital allocation, increasing reliance on management judgment across multiple quarters.
Concentration On GSK RoyaltiesA material reliance on royalties tied to a partner’s respiratory product sales concentrates revenue and cash risk. Product lifecycle, mix shifts or partner commercial performance can materially alter Innoviva’s cash flows for many quarters, limiting diversification of durable income sources.
Board Turnover And Related-Party FocusRecent board departures tied to executives’ focus on Syndeio and ongoing strategic/financial support create potential related-party exposure and management distraction. Over several quarters this can influence capital allocation, strategic priorities, and governance consistency.
Innoviva News
HVE FAQ
What was Innoviva’s price range in the past 12 months?
Innoviva lowest stock price was €14.20 and its highest was €21.20 in the past 12 months.
What is Innoviva’s market cap?
Innoviva’s market cap is €1.39B.
When is Innoviva’s upcoming earnings report date?
Innoviva’s upcoming earnings report date is Jul 29, 2026 which is tomorrow.
How were Innoviva’s earnings last quarter?
Innoviva released its earnings results on May 06, 2026. The company reported €1.945 earnings per share for the quarter, beating the consensus estimate of €0.342 by €1.603.
Is Innoviva overvalued?
According to Wall Street analysts Innoviva’s price is currently Undervalued.
Does Innoviva pay dividends?
Innoviva does not currently pay dividends.
What is Innoviva’s EPS estimate?
Innoviva’s EPS estimate is 0.38.
How many shares outstanding does Innoviva have?
Innoviva has 73,808,750 shares outstanding.
What happened to Innoviva’s price movement after its last earnings report?
Innoviva reported an EPS of €1.945 in its last earnings report, beating expectations of €0.342. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Innoviva?
Currently, no hedge funds are holding shares in DE:HVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€31.03 (52.12% Upside)
€31.03 (52.12% Upside)
Blogger Sentiment
Bullish
DE:HVE Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.41%
Trailing 12-Months
Company Description
Innoviva
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
HVE Stock 12 Month Forecast
Average Price Target
€31.03
▲(52.12% Upside)